Is prostaglandin E2 really of therapeutic value for postoperative urinary retention? Results of a prospectively randomized double-blind study

Wagner, G.; Husslein, P.; Enzelsberger, H.

doi:10.1016/0002-9378(85)90306-0

Cited by 21 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in a prospectively randomized double-blind study of 28 patients with urinary retention after anterior colporrhaphy, intravesical PGE 2 on postoperative days 6 and 7 showed no significant effect on PVRU compared with placebo [ 31 ]. Combination therapy of intravesical PGE 2 and oral bethanechol chloride showed limited benefit compared with the placebo combination [ 17 ].…”

Section: Pharmacological Therapymentioning

confidence: 99%

Current pharmacological and surgical treatment of underactive bladder

Kim

2017

Investig Clin Urol

View full text Add to dashboard Cite

Generally accepted guidelines are not yet available on the management of underactive bladder (UAB). Although the natural history of UAB is still not fully understood, observation may be an acceptable management option in patients with tolerable lower urinary tract symptoms and little risk of upper urinary tract damage. If needed, scheduled and double voiding may be recommended as an effective and safe add-on therapy. Parasympathomimetics have been widely used for the management of UAB, but the evidence does not support clinical benefit. The efficacy of alpha-blockers has also not yet been clearly demonstrated. However, selective alpha-blockers may help to enhance voiding efficiency and to decrease possible upper tract damage. Sacral neuromodulation is a surgical option for nonobstructive UAB approved by the Food and Drug Administration. However, the response rate of test stimulation is not high and the efficacy of permanent implants does not always coincide with that of test stimulation. Although surgery to reduce outlet resistance may be a viable option in UAB with presumed obstruction, surgery seems to have little role in those without obstruction. Latissimus dorsi detrusor myoplasty has shown promising results in restoring voluntary voiding in selected patients. The procedure requires a multidisciplinary team approach of urologists and plastic reconstructive experts. In summary, current treatments of UAB remain unsatisfactory. The multifactorial nature of UAB pathogenesis complicates the appropriate management for each patient. Future research to establish a more clinically relevant definition of UAB will be required to open new era of UAB management.

show abstract

Section: Pharmacological Therapymentioning

confidence: 99%

Current pharmacological and surgical treatment of underactive bladder

Kim

2017

Investig Clin Urol

View full text Add to dashboard Cite

show abstract

“…Theoretically, prostaglandin E2 would be suitable to restore voiding. In a randomized trial on urinary retention after abdominal hysterectomy with colposuspension, prostaglandin E2 was significantly more effective in restoring spontaneous voiding compared to placebo; however, in another trial following anterior colporraphy, prostaglandin E2 was not superior to placebo 30. Based upon the available literature, there are as yet no hard data to support the use of these drugs in restoring bladder function.…”

Section: Therapeutic Aspectsmentioning

confidence: 99%

What are the causes and consequences of bladder overdistension?: ICI‐RS 2011

Madersbacher

Cardozo

Chapple

et al. 2012

Neurourology and Urodynamics

View full text Add to dashboard Cite

ApBO is an important, but often unrecognized medical complication. There is a need for defining the terminology, for studies to record the incidence of different types of bladder overdistension, and to establish management strategies. Apart from clean intermittent self catheterization (CIC) there are no data justifying pharmacological or other therapies. Therefore, prevention is of paramount importance and there is a need to develop and test preventative strategies, which should then be incorporated in surgical registries.

show abstract

“…À visée curative, chez la femme (28 patientes) en rétention d'urine après colporaphie antérieure, les instillations endovési-cales de PGE2 (0,75 à 2,25 mg) n'influencent pas davantage qu'un placebo les aspects cliniques et urodynamiques de la miction [37]. À titre préventif, l'administration rectale ou vésicale de prostaglandine (respectivement 10 mg de PGE2 et 50 mg de PGF2) en postopératoire immédiat de chirurgie vaginale (50 patientes) ne modifie pas plus qu'une instillation de sérum salé la durée de drainage urinaire postopératoire, maintenu dans cette étude jusqu'à ce que les RPM soient inférieurs à 50 ml [38].…”

Section: Prostaglandinesunclassified

Traitement médical de l’hypoactivité vésicale

et al. 2007

View full text Add to dashboard Cite

L'hypoactivité du détrusor, définie par l'existence d'une contraction détrusorienne, réduite en force ou en durée déterminant une vidange vésicale prolongée ou un défaut de vidange complète dans un temps habituel [1,2], demeure un problème thérapeutique imparfaitement résolu. Les différentes classes pharmacologiques ayant fait l'objet d'application thérapeutique dans l'hypoactivité du détrusor (HOD), agonistes cholinergiques, anticholinestérasiques et prostaglandines visent à renforcer les capacités contractiles cholinodépendantes du détrusor. La médiation non adrénocholinergique du réflexe mictionnel n'a pas fait l'objet de développement thérapeutique dans cette indication. Cette mise au point corrige les résultats des travaux cliniques contrôlés évaluant l'intérêt clinique et/ou urodynamiques des agents cholinomimétiques dans l'hypoactivité vésicale (HOV). Leur pertinence thérapeu-tique, préventive ou curative, en monothérapie n'apparaît pas établie et l'intérêt de la combinaison d'agents pharmacologiques reste à confirmer.Abstract: Detrusor underactivity, defined as contraction of reduced strength or duration resulting in prolonged bladder emptying or failure to achieve complete bladder emptying within a normal time frame [1,2], remains challenging for pharmacological management. Several pharmacological agents have been proposed in the treatment of this condition, all targeting the cholinergic component of detrusor contractility. These include direct and indirect cholinergic drugs, anticholinesterasic agents and prostaglandin. Non-adrenocholinergic control of the micturition reflex is given little importance in the medical treatment of detrusor underactivity. This literature review focuses on data from controlled studies evaluating its pharmacological treatment. The preventive or curative efficacy of cholinomimetic drugs has not been established, and the effectiveness of combined therapy remains to be proved.

show abstract

Is prostaglandin E2 really of therapeutic value for postoperative urinary retention? Results of a prospectively randomized double-blind study

Cited by 21 publications

References 10 publications

Current pharmacological and surgical treatment of underactive bladder

Current pharmacological and surgical treatment of underactive bladder

What are the causes and consequences of bladder overdistension?: ICI‐RS 2011

Traitement médical de l’hypoactivité vésicale

Contact Info

Product

Resources

About